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Abstract
In this study, the effect of innate serum inhibitors on influenza virus infection was addressed. Seasonal influenza A(H1N1)
and A(H3N2), 2009 pandemic A(H1N1) (H1N1pdm) and highly pathogenic avian influenza (HPAI) A(H5N1) viruses were
tested with guinea pig sera negative for antibodies against all of these viruses as evaluated by hemagglutination-inhibition
and microneutralization assays. In the presence of serum inhibitors, the infection by each virus was inhibited differently as
measured by the amount of viral nucleoprotein produced in Madin-Darby canine kidney cells. The serum inhibitors inhibited
seasonal influenza A(H3N2) virus the most, while the effect was less in seasonal influenza A(H1N1) and H1N1pdm viruses.
The suppression by serum inhibitors could be reduced by heat inactivation or treatment with receptor destroying enzyme.
In contrast, all H5N1 strains tested were resistant to serum inhibitors. To determine which structure (hemagglutinin (HA)
and/or neuraminidase (NA)) on the virus particles that provided the resistance, reverse genetics (rg) was applied to
construct chimeric recombinant viruses from A/Puerto Rico/8/1934(H1N1) (PR8) plasmid vectors. rgPR8-H5 HA and rgPR8-
H5 HANA were resistant to serum inhibitors while rgPR8-H5 NA and PR8 A(H1N1) parental viruses were sensitive, suggesting
that HA of HPAI H5N1 viruses bestowed viral resistance to serum inhibition. These results suggested that the ability to resist
serum inhibition might enable the viremic H5N1 viruses to disseminate to distal end organs. The present study also
analyzed for correlation between susceptibility to serum inhibitors and number of glycosylation sites present on the
globular heads of HA and NA. H3N2 viruses, the subtype with highest susceptibility to serum inhibitors, harbored the
highest number of glycosylation sites on the HA globular head. However, this positive correlation cannot be drawn for the
other influenza subtypes.
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Introduction
Human and H5N1 avian influenza viruses are different in terms
of pathogenesis and severity of the disease. While the infections by
influenza A(H1N1), A(H3N2) and influenza B viruses are confined
mostly to the upper respiratory tract, the infection caused by
highly pathogenic avian influenza (HPAI) H5N1 viruses frequently
invades lower respiratory tract, induces cytokine storm, and causes
severe pneumonia which progresses to acute respiratory distress
syndrome and multi-organ failure [1,2]. Dissemination of H5N1
virus beyond the respiratory tract is well documented. The viral
RNA could be detected in the autopsies of several organs [3],
cerebrospinal fluid [4], and fetal tissues [5]. In addition, HPAI
H5N1 virus could be isolated from a plasma sample of a Thai
patient [6]. This information indicates that the propensity to
undergo viremic phase is not uncommon for HPAI H5N1 virus
infection. On the other hand, there has been just one recent report
on viremia in patients infected with the 2009 pandemic A(H1N1)
(H1N1pdm) virus [7]. Moreover, viremia associated with seasonal
influenza H1N1 and H3N2 viruses is very rare [8–10]. These
findings indicate that various influenza subtypes are different in
the capability to exhibit viremic phase.
Sera and respiratory fluids of mammals contain several innate
soluble factors that exhibit anti-influenza activity, for examples,
members of the collectin superfamily such as surfactant protein A
(SP-A), surfactant protein D (SP-D), conglutinin and mannose-
binding lectin (MBL) [11–13], member of the pentraxin
superfamily such as pentraxin 3 (PTX3) [14], and serum amyloid
P component [15]. The binding of human SP-D and MBL to both
hemagglutinin (HA) and neuraminidase (NA) can inhibit influenza
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through inhibition of viral neuraminidase activity, and hinder
viral infection by preventing viral attachment to the cell receptor.
The anti-influenza activities of human SP-D and MBL do not
involve other complement factors [16]. Interestingly, the highly
glycosylated seasonal H1N1 strains are sensitive to inhibition by
both SP-D and MBL, while the poorly glycosylated A/Puerto
Rico/8/1934(H1N1) (PR8) and H1N1pdm are resistant to either
one of them [17]. The long chain pentraxin, PTX3 inhibits several
strains of seasonal influenza A(H1N1), A(H3N2) and influenza B
viruses [14], though the susceptibility to PTX3 may be strain-
specific as some seasonal human influenza isolates including PR8
virus and the H1N1pdm viruses are resistant to PTX3 [17].
Complement, the major component of innate immunity, may play
anti-influenza activity independently or in adjunct with other
components. Activation of the complement system results in virus
aggregation, virolysis or opsonization [18]. It can lead to increased
vascular permeability and recruitment of phagocytic cells to
destroy the pathogens. MBL, together with complement in guinea
pig serum, exerted lytic activity on influenza virus infected-BHK-
21 cells through the classical pathway [19]. MBL also binds
influenza HA and activates complement through lectin pathway
[20]. Moreover, complement together with natural IgM antibody
can destroy virus through the classical pathway [21].
In the other system, non-specific inhibitors against influenza
viruses present in normal sera of various animal species were
classified into three types: a-, b-, and c-inhibitors based on their
chemical composition and several biological properties [22,23]. a-
inhibitors are heat- stable, but receptor destroying enzyme (RDE)-
sensitive glycoproteins. It inhibited influenza virus hemagglutina-
tion, but not influenza virus infectivity. The examples of a-
inhibitors found in serum are soluble mucoproteins. b-inhibitors
are non-sialylated, Ca
2+ dependent and heat-labile but RDE-
resistant. Study in bovine and mouse serum suggested that MBL
and SP-D belonged to b-inhibitors [24]; and MBL was
serologically cross reactive with human mannose-binding protein
(MBP) [20]. c-inhibitors are heat-stable and RDE-sensitive
sialylated glycoproteins which compete with cellular receptor for
binding with HA; these inhibitors neutralize viral infectivity by
blocking the attachment step in the influenza virus replication
cycle [23,25]. In horse, guinea pig and mouse sera, c-inhibitor had
been identified as a2-macroglobulin [25,26]. In addition, the study
in murine model also demonstrated that the a2-macroglobulin
could inhibit hemagglutination inhibition (HI) assay, but its
activity on microneutralization (microNT) assay against various
viruses expressing H3N2 HA was varied among H3N2 isolates
[26].
For the influenza viruses to exhibit viremic phase, they should
be able to overcome the inhibition by innate serum inhibitors.
Therefore, the ability of HPAI H5N1 viruses to spread beyond the
respiratory tract is suggestive of their ability to resist the serum
inhibitors. Herein, guinea pig sera were used as the model to study
serum innate immunity against various influenza viruses of human
and avian origins, including seasonal H1N1, H3N2, H1N1pdm,
and HPAI H5N1 viruses. The nature of inhibitors was
characterized by their sensitivity to heat or RDE treatment. We
demonstrated that HPAI H5N1 virus was the only subtype that
could resist the inactivation by serum innate inhibitors. Using
reverse genetics, the viral resistance to serum inhibitors could be
mapped to HA. Our finding suggested a novel pathogenic
mechanism on H5N1 virus dissemination beyond the respiratory
system.
Results
Biological properties of the guinea pig sera
In order to determine role of serum inhibitors against influenza
viruses, it is necessary to screen that the test guinea pig sera
contained no specific antibodies against the study viruses.
Otherwise, it would be difficult to differentiate between inhibitory
effects mediated by the serum specific inhibitors and specific
antibodies. Sera of three guinea pigs from different batches of
animals were screened for specific antibody against all 14 influenza
virus isolates and 4 reassorted viruses by HI and microNT assays.
The result showed that none of the test sera contained pre-existing
HI or NT antibody as screened at the initial serum dilution 1:10
(data not shown).
It has been known that some serum innate inhibitors are heat-
labile and some are heat-stable. There is no control measure to
determine stability of those unknown heat-labile components in
the stored sera during the on going experiments. Therefore, our
study used complement as the representative of heat-labile
components based on its abundant amount in guinea pig sera
and availability of the measurement method. We assumed that if
complement in the test sera did not deteriorate, the other heat-
labile components should remain in good condition. Each guinea
pig serum was measured for complement titer by complement
fixation test using hemolysin sensitized-sheep red blood cells
(SRBCs) as the indicator system. We also showed that the three
guinea pigs used in our experiments contained comparable serum
concentrations of complement, i.e., 32–64 complement hemolytic
units; in another word, the serum dilution of 1:32 or 1:64
contained one complement hemolytic unit. The native sera and
heat-inactivated sera were assayed in parallel for their lytic activity
on hemolysin sensitized- SRBCs. The result demonstrated that the
native sera completely lysed the sensitized-SRBCs, while the lytic
activity was eradicated after heat inactivation.
Furthermore, the sera were diluted to contain the complement
concentrations of 0.25, 0.5, 1, 2, 4 and 8 hemolytic units and
assayed against the seasonal A(H1N1) (SI-RA-TT/04), seasonal
A(H3N2) (SI 03/04), H1N1pdm (Nonth/102/09) and HPAI
H5N1 (KAN-1) viruses in order to determine the optimal dilutions
that could exert anti-influenza activity. The result showed a slight
increase in the percentages of viral inhibition when serum
complement concentrations were greater than two hemolytic units
(Figure 1). Therefore, the concentration of 2 complement
hemolytic units was employed in subsequent experiments.
Determination for activity of serum innate inhibitors
against various influenza subtypes
Guinea pig sera were used as source of innate inhibitors in the
assay for infection inhibition against influenza viruses. The study
viruses at concentration of 1,000 TCID50/50 ml (TCID50; 50%
tissue culture infectious dose) were incubated with native guinea
pig serum at working dilution which contained complement
concentration of 2 hemolytic units. The virus-serum mixture in
quadruplicate was inoculated onto Madin-Darby canine kidney
(MDCK) cell monolayers for overnight. Infectivity of the viruses
which were susceptible to serum innate inhibitors should be
inhibited and resulted in the decreased amount of viral
nucleoprotein produced in the infected MDCK cells as deter-
mined by enzyme-linked immunosorbent assay (ELISA). Based on
the percentages of viral infection inhibition as compared to the
virus control, H3N2 viruses were the subtype most susceptible to
serum inhibitors (81–100% inhibition); and followed in order by
H1N1pdm (34–89% inhibition) and seasonal H1N1 viruses (21–
62% inhibition) (Table 1 and Figure 2). In contrast, all HPAI
HPAI H5N1 Viral Resistance to Serum Inhibitors
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percentages of inhibition of less than 10, except one serum which
exerted 19% inhibition against KAN-1, and 12% inhibition
against NBL (feces in origin) viruses (Table 1).
Biochemical nature of serum innate inhibitors and the
viral susceptibility
Heat-inactivated serum or RDE-treated+heat-inactivated serum
was assayed for their viral inhibitory effect against various
influenza subtypes/strains in comparison with the native serum
control. Statistically significant difference in the percentage of
inhibition was considered at p#0.05. Each serum was assayed in
quadruplicate and the percentages of viral inhibition of all 3
guinea pig sera were averaged. The viral inhibition effects exerted
by native sera, heat-inactivated sera and RDE-treated+heat-
inactivated sera are shown as the histograms in Figure 2.
Among H1N1 viruses (Figure 2A), PR8 virus was the most
susceptible to serum inhibitors (62% viral inhibition) and followed
in order by SI 3043/09 and SI-RA-TT/04. Nevertheless, the
inhibitory activity against PR8 decreased to almost 4% when the
viruses were treated with either heat-inactivated sera or RDE-
treated+heat-inactivated sera. Thus, the PR8 virus was susceptible
to heat-sensitive inhibitors only, as the addition of RDE (in the
RDE-treated+heat-inactivated sera) did not further decrease the
percentages of viral inhibitory activity. Similarly, SI 3043/09 was
also inhibited by native serum; and percentages of viral inhibition
decreased from 31% to 15% with heat-inactivated sera, and to
12% with RDE-treated+heat-inactivated sera. As the decrease in
the percentages of inhibition from 15 to 12% was not statistically
significant, it is interpreted that SI 3043/09 was susceptible to
heat-labile inhibitors, but susceptibility to RDE-sensitive inhibi-
Figure 1. Anti-influenza activities of guinea pig sera at various
complement hemolytic units. Native guinea pig sera at various
complement hemolytic units were incubated with seasonal H1N1 (SI-
RA-TT/04), H3N2 (SI 03/04), H1N1pdm (Nonth/102/09) or HPAI H5N1
(KAN-1/04) virus followed by inoculation the serum-virus mixture onto
MDCK cell monolayers. After an overnight incubation, the viral
inhibitory activity of the test serum was measured by determining
the amount of viral nucleoprotein produced in the inoculated MDCK
cells by ELISA. The results are shown as mean of the percentages of viral
inhibition derived from quadruplicate experiments. Error bars represent
the standard deviation.
doi:10.1371/journal.pone.0036318.g001
Table 1. Presence of inhibitory factors against influenza viruses in guinea pig sera.
% inhibition of viral infection mediated by
guinea pig sera
Subtype Virus name Abbreviations No. 1 No. 2 No. 3
Seasonal H1N1 A/PR/8/34 (reassorted virus) PR8 47.7 56.9 62.1
A/Thailand/Siriraj-Rama-TT/04 (A/New Caledonia/20/
99-like virus)
SI-RA-TT/04 21.9 23.3 21.0
A/Thailand/Siriraj3043/09 (A/Brisbane/59/07-like
virus)
SI 3043/09 37.9 31.8 30.7
Seasonal H3N2 A/Thailand/Siriraj-08/98 (A/Sydney/05/97-like virus) SI 08/98 82.6 82.2 80.9
A/Thailand/Siriraj-06/02 (A/Moscow/10/99-like virus) SI 06/02 88.7 87.0 100
A/Thailand/Siriraj-02/03 (A/Fujian/411/02-like virus) SI 02/03 99.5 97.1 96.2
A/Thailand/Siriraj-03/04 (A/Fujian/411/02-like virus) SI 03/04 94.9 97.2 96.9
H1N1pdm A/Thailand/104/09 Thai/104/09 51.6 65.0 34.2
A/Nonthaburi/102/09 Nonth/102/09 81.2 80.8 83.7
A/California/07/09 CA/07/09 86.7 85.3 88.7
HPAI H5N1 A/Thailand/1(KAN-1)/04 KAN-1 8.9 18.6 5.5
A/Thailand/676(NYK)/05 676(NYK) 0 2.9 6.0
A/Thailand/NBL-1/06 (feces) NBL feces 6.8 12.0 9.8
A/Thailand/NBL-1/06 (lung) NBL lung 7.3 6.5 5.2
A/Laos/Nong Khai 1/07 Nong Khai 1 3.4 7.6 0.8
H5 reverse genetics rgPR8-H5 HANA (KAN-1) rgPR8-H5 HANA 1.9 7.1 6.4
rgPR8-H5 HA (KAN-1) rgPR8-H5 HA 0 4.6 1.6
rgPR8-H5 NA (KAN-1) rgPR8-H5 NA 80.0 41.6 84.9
doi:10.1371/journal.pone.0036318.t001
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TT/04 was susceptible to both heat-sensitive inhibitors and RDE-
sensitive inhibitors as the percentages of viral inhibition dropped
from 21% to 13% or 1% after treatment with heat-inactivated sera
or RDE-treated+inactivated sera, respectively.
Among H1N1pdm (Figure 2B), percentages of inhibition of
Thai/104/09 virus as assayed against native sera, heat-inactivated
sera and RDE-treated+heat-inactivated sera were 34, 15 and 5%,
respectively. This result showed that Thai/104/09 virus was
susceptible to heat-labile serum inhibitors; however, its suscepti-
bility to RDE-sensitive inhibitors could not be drawn statistically.
On the other hand, percentages of inhibition of Nonth/102/09
virus as assayed with native sera, heat-inactivated sera and RDE-
treated+heat-inactivated sera were 84, 81 and 42%, respectively.
The data suggested that Nonth/102/09 virus was partially
susceptible to RDE-sensitive inhibitors. The percentages of viral
inhibition of CA/07/09 virus as assayed with native sera, heat-
inactivated sera and RDE-treated+heat-inactivated were 89, 74,
and 8%, respectively. The result suggested that CA/07/09 virus
was slightly susceptible to heat-labile inhibitors, but highly
susceptible to RDE-sensitive inhibitors.
Interestingly, all H3N2 viruses were highly susceptible to native
serum with percentages of viral inhibition greater than 80%
(Figure 2C). SI 08/98, SI 06/02 and SI 02/03 were susceptible to
both heat-labile inhibitors and RDE-sensitive inhibitors. Such that
the percentages of viral inhibition dropped from 81 to 5% for SI
08/98, from 100 to 20% for SI 06/02, and from 96 to 49% for SI
02/03, as the results obtained from the assays with native sera
were compared with those employed heat-inactivated sera; and
also, the percentages of viral inhibition dropped from 5 to 0% for
SI 08/98, from 20 to 0% for SI 06/02, and from 49 to 3% for SI
02/03, as the results obtained from the assay with heat-inactivated
sera were compared with those employed RDE-treated+heat-
inactivated sera. The statistical analyses were significantly different
for those comparisons. On the other hand, SI 03/04 was
susceptible to heat-labile inhibitors alone as shown by the
significant decrease in the percentages of viral inhibition from 97
to 22% as the assays with native sera were compared with those
employed heat-inactivated sera. In contrast, the percentages of
viral inhibition which decreased from 22% (as assayed with heat-
inactivated sera) to 12% (as assayed with RDE-treated+heat-
inactivated sera) was not significantly different.
Owing to low susceptibility of the HPAI H5N1 viruses to native
guinea pig sera (the mean percentage of viral inhibition of 11, 3,
10, 6, and 4 for KAN-1, 676(NYK), NBL feces, NBL lung, and
Nong Khai 1, respectively), the assays employing heat-inactivated
serum as well as RDE-treated+heat-inactivated serum were not
performed.
Role of HA on viral resistance to serum innate inhibitors
Owing to the difference in susceptibility to serum innate
inhibitors among various influenza subtypes, it is speculated that
HA and/or NA play a key role in this difference. To elucidate this
speculation, reassorted PR8 virus together with three reverse
genetic viruses harboring HA and/or NA genes from HPAI H5N1
(KAN-1) viruses in PR8 backbone, i.e., rgPR8-H5 HANA (6+2
Figure 2. Inhibitory activities of native guinea pig serum, heat-
inactivated serum, and RDE-treated+heat-inactivated serum
against influenza viruses. Guinea pig sera were incubated with (A)
H1N1 viruses, (B) H1N1pdm viruses, or (C) H3N2 viruses. The viral
inhibitory activities of the test sera were determined in MDCK cells
inoculated with the serum-virus mixtures by ELISA. The results are
shown as mean of the percentages of viral inhibition derived from
quadruplicate experiments. Error bars represent the standard deviation.
* There are statistically significant differences between the inhibitory
activity of the native serum and the heat-inactivated serum or the
native serum and the RDE-treated+heat-inactivated serum (p#0.05).
** There are statistically significant differences in the inhibitory activity
between heat-inactivated serum and RDE-treated+heat-inactivated
serum (p#0.05).
doi:10.1371/journal.pone.0036318.g002
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were tested against guinea pig sera. The result showed that
reassorted PR8 parental virus and rgPR8-H5 NA could be
inhibited by serum innate inhibitors with 48–62% and 42–85%
viral inhibition, respectively (Table 1). In contrast, rgPR8-H5 HA
and rgPR8-H5 HANA could resist the serum inhibitors with
percentages of viral inhibition of only 0–5% for rgPR8-H5 HA
and 2–7% for rgPR8-H5 HANA, similarly to the H5N1 wild type
viruses. When the viral inhibitory activity of native serum, heat-
inactivated serum and RDE-treated+heat-inactivated serum were
compared, the result showed that efficiency to inhibit reassorted
PR8 parental virus and rgPR8-H5 NA viruses were almost
completely lost simply by heat inactivation alone; and thus, the
inhibitory effect from RDE could not be seen (Figure 3). No
significant change in percentages of viral inhibition was observed
with rgPR8-H5 HA and rgPR8-H5 HANA viruses when reacted
with either heat-inactivated serum or RDE-treated+heat-inacti-
vated serum. The results were reproducible with all three guinea
pig serum samples tested (Table 1). In conclusion, it was the HA
not NA that rendered HPAI H5N1 viruses the resistance to serum
inhibitors.
Prediction of the potential N-linked glycosylation sites on
HA and NA globular domains
Our previous experiments demonstrated that HA determined
the viral susceptibility or resistance to serum innate inhibitors.
Additionally, previous groups of investigators reported that an
increase in glycosylation site in HA protein resulted in the
increased susceptibility to innate inhibitory factors such as SP-D
and collectins [27,28]. Therefore, our study viruses were predicted
for their potential sites of glycosylation in HA and NA molecules
by CountGS application in BioEdit program version 7.0.4.1 [29].
HA and NA sequences of the study viruses are retrieved from the
GenBank database using the accession numbers as shown in
Table 2. The potential N-linked glycosylation motif was defined as
Asn-X-Ser/Thr, where X may represent any amino acids except
proline. The present study determined number of glycosylation
sites in the HA globular head of the study viruses, defining that the
globular head is situated between the loop region flanked with a
conserved disulfide bond in the cysteine bridge in HA1 domain
[30]. With methionine as the start position, the globular heads are
situated between amino acid position 59 to 291 (reassorted PR8
and seasonal H1N1 viruses), 59 to 292 (H1N1pdm viruses), 68 to
293 (seasonal H3N2 viruses), and 58 to 290 (HPAI H5N1 viruses).
The results showed that H3N2 viruses, the most susceptible
subtype to serum inhibitors, contained highest number of
glycosylation sites in HA. On the other hand, reassorted PR8
and H1N1pdm viruses which were moderately susceptible to
serum innate inhibitors contained one glycosylation site on the HA
globular head, while the resistant H5N1 viruses harbored 2
glycosylation sites (Table 2). A homology-based structural model of
the HA molecules of seasonal H1N1 (SI-RA-TT/04), H1N1pdm
(Thai/104/09), seasonal H3N2 (SI 03/04) and HPAI H5N1
(KAN-1) viruses were constructed using HA crystal structures of
PR8, A/California/04/09, A/X-31 (H3N2) or A/HK/212/03
(H5N1) (PDB codes: 1RU7, 3LZG, 1HGF and 3FKU, respec-
tively) as the template. All three-dimensional models are generated
by Chimera program version 1.5.3 [31] as shown in Figure 4.
Amino acid positions that are the potential N-linked glycosylation
sites on globular head of HA were predicted for reasserted PR8
(Asn285), seasonal H1N1 (Asn71, Asn104, Asn142 and Asn176),
H1N1pdm (Asn104), seasonal H3N2 (Asn79, Asn138, Asn142,
Asn149, Asn160, Asn181 and Asn262, but Asn160 was not found
in SI 08/98 (H3N2)), and H5N1 (Asn170 and Asn181).
Number of glycosylation sites on NA of the study viruses is
shown in Table 2. Based on NA crystal structures of A/Brevig
Mission/1/18 (H1N1) and A/Memphis/31/98 (H3N2) (PDB
codes: 3BEQ and 2AEP, respectively) with methionine as the start
position, the globular head domain of N1 NA starts at position 83
to 468 (N1 numbering) and that of N2 NA starts at position 82 to
469 (N2 numbering). Amino acid positions that are the potential
N-linked glycosylation sites on globular head of NA were predicted
for reassorted PR8 (Asn88 and Asn235), seasonal H1N1 (Asn88,
Asn146, Asn235, Asn434 and Asn455), H1N1pdm (Asn88,
Asn146, Asn235 and Asn385), seasonal H3N2 (Asn86, Asn146,
Asn200, Asn234, Asn392 and Asn402, but additional site, Asn93,
was found in SI 06/02), and H5N1 viruses (Asn126, Asn215, but
additional site, Asn321, was found in 676(NYK), and Asn366 was
found in Nong Khai 1 virus).
Discussion
Most of human sera contain pre-existing anti-influenza
antibodies as the results of vaccinations or past infections with
some influenza subtypes. Therefore, guinea pig sera instead of
human sera were used as the model to study innate immunity
Figure 3. Inhibitory activities of native guinea-pig serum, heat-
inactivated serum, and RDE-treated+heat-inactivated serum
against reverse genetic viruses. Guinea pig sera were incubated
with rgPR8 viruses that contain HPAI H5N1 HANA, HA alone or NA
alone. The viral inhibitory activities of the test sera were determined in
MDCK cells inoculated with the serum-virus mixtures by ELISA. The
results are shown as mean of the percentages of viral inhibition derived
from quadruplicate experiments. Error bars represent the standard
deviation. * There are statistically significant differences between the
inhibitory activity of the native serum and the heat-inactivated serum or
the native serum and the RDE-treated+heat-inactivated serum (p#0.05).
** There are statistically significant differences in the serum inhibitory
activity as compared between the reassorted PR8 virus and the rgPR8-
H5 HA virus or the reassorted PR8 virus and the rgPR8-H5 HANA
(p#0.05).
doi:10.1371/journal.pone.0036318.g003
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human specific antibody which might create miss-interpretation in
the viral infection inhibition assay. Nevertheless, it has been shown
that the serum components such as MBL and SP-D are presented
in both guinea pig and human sera [11–13]. To some extents and
with a careful interpretation, our results from guinea pig should be
able to extrapolate to humans. Additionally, to ascertain that the
guinea pig sera were also free from anti-influenza antibodies, the
sera were tested negative against all study viruses at the screening
dilution of 1:10 by HI and microNT assays.
Our viral infection inhibition assay demonstrated that among 10
human influenza viruses (reassorted PR8, 2 seasonal H1N1, 4
seasonal H3N2 and 3 H1N1pdm viruses) tested, 5 were susceptible
to both heat-inactivated sera and RDE-treated+heat-inactivated
sera, 4 were susceptible to heat-inactivated sera only and 1 was
susceptible to RDE-treated+heat-inactivated sera only, with
degree of inhibition varying to virus subtypes and strains within
the same subtype. H3N2 subtype was the most susceptible to
serum inhibitors, while seasonal H1N1 and H1N1pdm viruses
were moderately susceptible. All HPAI H5N1 isolates tested were
highly resistant to serum inhibitors. While the identities of the
serum inhibitors were not determined in our study, the class of
serum innate immunity could be estimated from the viral
inhibition effects after the sera were treated with heat or
RDE+heat. Since a-inhibitors can inhibit only hemagglutination
but not virus infection [22,23], they are likely not contributing to
the virus inhibition observed in our experiments. On the other
hand, our results suggested that serum innate inhibitors against the
non H5N1 influenza viruses could be b-inhibitors which are heat-
labile and RDE-resistant, c-inhibitors which are heat-stable and
RDE-sensitive, and complement which is heat-labile.
While most of investigators utilized individual serum factors
such as SP-D, SP-A, MBL or PTX-3 to study influenza innate
immunity, serum factors are likely to work together to exert their
anti-influenza activities. In addition, there might be several more
anti-influenza factors in sera that have not been discovered yet;
thus, complicating the interpretation of the results in broader
picture of pathogenesis. The activity of individual factor may not
represent overall inhibitory activity observed in the native serum.
For example, investigators previously reported that PR8 virus was
resistant to MBL [17], and SP-D [27]; however, the present study
demonstrated that our reassorted PR8 virus was sensitive to native
guinea pig sera with 48–62% viral inhibition activity. The effect of
reverse genetics manipulation on susceptibility to serum inhibitors
has been excluded as our rgPR8-H5 NA was sensitive while
rgPR8-H5 HA and rgPR8-H5 HANA were resistant to the serum
inhibitors. Therefore, our system of using whole serum to examine
anti-influenza innate serum inhibitors provides a suitable platform
to dissect how the HPAI H5N1 virus could disseminate to distal
organs.
Number of glycosylation sites on the envelope glycoprotein, HA
in particular, has been correlated to the susceptibility of influenza
viruses to innate serum inhibitors [28]. Our study showed that
H3N2, the most susceptible subtype, has the highest number of
glycosylation sites on HA as compared to the other virus subtypes,
with 11–12 sites on the H3N2 complete HA amino acid sequences
and 6–7 sites on the globular head. A previous study demonstrated
that high degree of N-linked glycosylation could attenuate H3N2
influenza viruses. The addition of oligosaccharide moieties to
globular head of HA had been linked to increased sensitivity of
H3N2 viruses to SP-D and MBL [32]. Glycosylation sites on HA
have accumulated in the human influenza H3N2 virus since its
appearance in 1968. This gain of sites and their long-term
maintenance are presumed to be due to a selective advantage of
glycosylation [33]. Extensive evidences indicated that glycosylation
plays important roles in the life cycle of influenza viruses by
conferring structural integrity and stability of virus particles as well
as modulating the functions of HA and NA in the recognition of
Table 2. Potential glycosylation sites on HA and NA proteins of the study viruses.
Accession number Number of glycosylation sites on
Virus name HA NA HA
Globular head
of HA NA
Globular head
of NA
A/PR/8/34 (reassorted virus H1N1) EF467821 EF467823 7 1 4 2
A/Thailand/Siriraj-Rama-TT/04 (H1N1) JN676132 JN676133 10 4 9 5
A/Thailand/Siriraj3043/09 (H1N1) JN676130 JN676131 10 4 9 5
A/Thailand/104/09 (H1N1) GQ169382 GQ169381 8 1 8 4
A/Nonthaburi/102/09 (H1N1) GQ150342 GQ150343 8 1 8 4
A/California/07/09 (H1N1) FJ969540 HM138502 8 1 8 4
A/Thailand/Siriraj-08/98 (H3N2) JN617980 JN617985 11 6 8 6
A/Thailand/Siriraj-06/02 (H3N2) JN617982 JN617984 12 7 9 7
A/Thailand/Siriraj-02/03 (H3N2) JN617979 JN617983 12 7 8 6
A/Thailand/Siriraj-03/04 (H3N2) JN617981 JN617986 12 7 8 6
A/Thailand/1(KAN-1)/04 (H5N1) AY555150 AY555151 8 2 3 2
A/Thailand/676(NYK)/05 (H5N1) DQ360835 DQ360836 8 2 4 3
A/Thailand/NBL1/06 (H5N1) lung GQ466176 GQ466177 8 2 3 2
A/Laos/Nong Khai 1/07 (H5N1) EU499372 EU499378 8 2 4 3
rgPR8-H5 HANA (KAN-1) AY555150 AY555151 8 2 3 2
rgPR8-H5 HA (KAN-1) AY555150 - 8 2 4 2
rgPR8-H5 NA (KAN-1) - AY555151 7 1 3 2
doi:10.1371/journal.pone.0036318.t002
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oligosaccharides on the virus envelope were shown to be a target
for recognition and destruction by lectins of the innate immune
system [35]. Based on the data obtained from H3N2 viruses, it is
likely that the degree of viral neutralizing activity of our guinea pig
sera was positively correlated to number of glycosylation sites
Figure 4. Potential N-linked glycosylation sites on HA globular domain. HA1 chains are displayed as space-filling models in HA trimer, while
HA2 chains are displayed as ribbon. One of the three HA1 chains is highlighted in lighter shade than the other two HA1 chains. Model of H1N1pdm is
related to models of PR8 by 60-degree counterclockwise rotation on vertical axis. The top view is related to the side view by 90-degree rotation on
horizontal axis.
doi:10.1371/journal.pone.0036318.g004
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human influenza subtypes does not support this hypothesis. Our
reassorted PR8 and H1N1pdm viruses, which are moderately
susceptible to serum inhibitors, contain only one glycosylation site
on the HA globular head; while HPAI H5N1 viruses, which are
the most resistant subtype, contain two sites. These findings
suggested that the viral domains other than glycosylation sites on
HA globular head could be the target for binding with serum
innate inhibitors. In addition, our previous work also suggested
that receptor binding site might not be the target of recognition by
the serum inhibitors as 676(NYK) which preferred human type
receptor (sialic acid-linked a2,6-galactose) was as resistant as the
other H5N1 isolates which preferred avian type receptor (sialic
acid-linked a2,3-galactose) [36].
Previous studies have shown genetic elements that contribute to
the H5N1 viral virulence such as glutamine to lysine substitution at
amino acid position 627 in PB2, the presence of multiple basic
amino acids at the HA cleavage site, and the presence of a
sequence motif, Glu-Ser-Glu-Val at the carboxyl terminus of NS1
protein [37]. Herein, our study suggests a novel mechanism to
virulence of HPAI H5N1 viruses through their ability to resist
serum innate immunity, enabling the viruses to disseminate
beyond the respiratory tract, the primary organ of infection, to
various visceral organs. The disseminated viruses may subsequent-
ly exert their immunopathological effect via an induction of
cytokine storm and multi-organ failure, the hallmarks of HPAI
H5N1 in humans.
Materials and Methods
Guinea pig sera
Guinea pig blood was purchased from the National Laboratory
Animal Center, Mahidol University. When the blood clot
retracted, serum was separated by spinning at 2,000 rpm in a
refrigerated centrifuge, and then aliquoted and stored at 280uC.
Guinea pig sera were negative for antibody to all study influenza
viruses as determined by HI and microNT assays.
The viruses
Influenza A viruses in this study including seasonal H1N1 and
H3N2, H1N1pdm and HPAI H5N1 viruses (Table 1), were
propagated in MDCK cells (obtained from the American Type
Culture Collection; CCL-34). These virus isolates were kindly
provided by Siriraj Influenza Cooperative Research Center; and
the routine service laboratory, Department of Microbiology,
Faculty of Medicine Siriraj Hospital, Mahidol University.
Construction of influenza reassortants by reverse
genetics
The pHW reverse genetic system [38] comprising 8 recombi-
nant plasmids containing PA, PB1, PB2, NP, HA, NA, M or NS
genomic segments derived from the parental PR8 virus were
kindly provided by Prof. Robert Webster and Dr. Erich Hoffman,
St. Jude Children Research Hospital, Memphis, Tennessee, USA.
Three kinds of reverse genetic viruses harboring HA, NA, or both
HA and NA genes derived from A/Thailand/1(KAN-1)/04
(H5N1) viruses were constructed. HA and NA genomic segments
were amplified by RT-PCR using universal primers [39] and
cloned individually into pHW2000 vector. HA segment (accession
number AY555150) was engineered to eliminate the multiple basic
amino acids at HA cleavage site (337-PQRERRRKKR-346 was
changed to 337-PQ----IETR-346, H5 numbering) which mimics
the cleavage site of the low pathogenic avian H6 virus before
cloning; while the NA segment (accession number AY555151) was
cloned unmodified. To construct the reverse genetic viruses,
rgPR8-H5 HA (7+1), rgPR8-H5 NA (7+1) and rgPR8-H5 HANA
(6+2) viruses, 1 mg of each of the 8 recombinant plasmids were
transfected into HEK-293 cells co-culturing with MDCK cells
using TransITH-LT1 Transfection Reagent (Mirus Bio LLC,
Madison, WI). After 24 hours, the reassortants were rescued by
adding with 1 ml of Opti-MEMH I Reduced Serum Medium
(Invitrogen, Carlsbad, CA) containing 2 mg/ml of TPCK-treated
trypsin (Sigma, St. Louis, MO). The culture plate was further
incubated at 37uC for 24–48 hours, observed for cytopathic effect
and screened for progeny viruses released in the culture
supernatant by hemagglutination assay. In addition, all 8 pHW
recombinant plasmids containing each gene of PR8 origin were
transfected into HEK-293 cells co-culturing with MDCK cells to
generate reassorted PR8 virus as the control of the experiments.
The reassortants were propagated and titrated in MDCK cells.
HI assay
HI assay was performed based on the protocol as described in
the WHO manual [40]. Goose RBCs were employed in the assay
for antibody to HPAI H5N1 and H1N1pdm. On the other hand
guinea pig RBCs were employed in the assay for antibody to the
other human influenza viruses. Briefly, 50 ml of guinea pig serum
was mixed with 150 ml of RDE (Denka Seiken Co. Ltd., Tokyo,
Japan) and incubated at 37uC for 16–18 hours to eliminate the
nonspecific inhibitors. The treated serum was inactivated at 56uC
for 30 minutes and absorbed with the test RBCs to remove
nonspecific agglutinators. The replicating influenza virus at the
final concentration of 4 hemagglutination units/25 ml was used as
the test antigen. The treated serum was serially two-fold diluted at
an initial dilution of 1:10 into a final volume of 25 ml per well
before 25 ml of the test antigen was added. After incubation at
room temperature for 30 minutes, 50 ml of 0.5% goose RBCs (for
HI antibody to H1N1pdm and H5N1 viruses) or 0.75% guinea pig
RBCs (for HI antibody to seasonal H1N1 and H3N2 viruses) were
added into every well and further incubated the reaction plate at
4uC 30 minutes (for goose RBCs) or 60 minutes (for guinea pig
RBCs). HI titer was defined as the reciprocal of the last serum
dilution that completely inhibited hemagglutination of RBCs.
MicroNT assay
Guinea pig sera were screened for the antibodies to the test
influenza viruses by microNT assay using the protocol as described
previously [40]. Guinea pig serum was treated with RDE before
heat inactivation at 56uC for 30 minutes. The treated sera were
serially two- fold diluted with 1X EMEM at an initial dilution of
1:10 in a microtiter plate. The diluted serum was incubated with
the test virus at the final concentration of 100 TCID50/100 ml for
2 hours at 37uC. Then, 100 ml of each virus-antibody mixture was
transferred onto the MDCK cell monolayer maintained in EMEM
supplemented with trypsin TPCK (Sigma, St. Louis, MO), and
incubated overnight at 37uC, 5% CO2. The inoculated MDCK
cell monolayers in the reaction plates were fixed with 80% acetone
prior to determining for presence of viral nucleoprotein by ELISA.
Antibody titer was defined as the highest serum dilution that
yielded a 50% reduction in the amount of nucleoprotein as
compared to the virus infected cell control.
Complement titration
Guinea pig serum contains many soluble factors, including
complement factors that confer activity against influenza virus.
The amount of complement present in each guinea pig serum can
be measured by titration against hemolysin-sensitized SRBCs [41].
Equal volume of 2% SRBCs was mixed with appropriate
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1 hour with shaking at intervals to obtain hemolysin sensitized
SRBCs. The test guinea pig serum was serially two-fold diluted
with veronal buffer to obtain a volume of 25 ml per well in a U-
shaped microtiter plate. Then, the serum was incubated with
hemolysin sensitized SRBCs for 45 minutes with shaking at
intervals. In the presence of serum complement, the sensitized
SRBCs would be lysed; while the SRBCs and sensitized SRBC
controls appeared as a red button at the bottom of the well. One
hemolytic unit was defined as the highest dilution of complement
which yielded complete hemolysis of the sensitized SRBCs. Owing
to heat-labile nature of the complement proteins, guinea pig sera
were stored at 270uC; and complement titration was conducted
prior to each use.
Assay for inhibition of influenza virus infection by soluble
factors in guinea pig serum
Guinea pig serum at the working concentration of 2
complement hemolytic units was incubated with the test virus at
a final concentration of 1,000 TCID50/50 mla t3 7 uC for
45 minutes in quadruplicate wells. Then, the mixtures were
transferred onto MDCK cell monolayers and incubated overnight
at 37uC prior to measuring the amount of viral nucleoprotein in
the infected MDCK cell monolayers by ELISA. In the presence of
serum inhibitors, viral infection was blocked, resulting in the
decreased amount of viral nucleoprotein synthesized in the
inoculated culture as compared to the infected MDCK cell
controls. In the case where serum inhibitors could not inhibit viral
infection, the high O.D. values indicating viral nucleoprotein
synthesis would be observed. The percentages of viral inhibition
were calculated based on the O.D. values as compared to the virus
control without serum.
The assay employed native guinea pig serum was conducted in
parallel with the heat-inactivated serum and together with the
RDE-treated+heat-inactivated serum. Heat treatment to inacti-
vate the b-inhibitors was performed by treating the guinea pig
serum at 56uC for 30 minutes and then cooled on ice. RDE
treatment was conducted to destroy a- and c-inhibitors such that
the guinea pig serum was mixed with RDE according to the
protocol used for HI assay, followed by heat inactivation at 56uC
for 30 minutes to get rid of RDE activity and b-inhibitors.
ELISA
ELISA for influenza viral nucleoprotein was performed with
mouse specific monoclonal antibody against influenza nucleopro-
tein (Catalog number MAB8257, Millipore Corporation, Teme-
cula, CA) as the primary antibody. Horseradish peroxidase (HRP)-
conjugated goat anti-mouse Ig (Catalog number 1010-05,
Southern Biotech, Birmingham, AL) was used as the secondary
antibody. The optical density was measured at dual wavelengths of
450/630 in a spectrophotometer.
Statistical analysis
Statistical analysis was done with PASW Statistics 18 software.
The percentages of viral inhibition by native sera, heat-inactivated
sera and RDE-treated+heat-inactivated sera were analyzed using
analysis of variance (ANOVA). Difference between two data sets
was examined using Student’s t-test. The significance level was set
at p#0.05.
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